Form 8-K - Current report:
SEC Accession No. 0001193125-25-024005
Filing Date
2025-02-11
Accepted
2025-02-11 08:11:58
Documents
15
Period of Report
2025-02-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d905966d8k.htm   iXBRL 8-K 26053
2 EX-99.1 d905966dex991.htm EX-99.1 27608
6 GRAPHIC g905966g0211031542881.jpg GRAPHIC 2334
  Complete submission text file 0001193125-25-024005.txt   190623

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inab-20250211.xsd EX-101.SCH 2835
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inab-20250211_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inab-20250211_pre.xml EX-101.PRE 11697
17 EXTRACTED XBRL INSTANCE DOCUMENT d905966d8k_htm.xml XML 3752
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39692 | Film No.: 25607726
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)